# Artifact Evaluations by CT-Scalability (Iteration 2)

> Schema: `.github/agents/evaluation-schema.md`

```yaml
artifact_evaluation:
  evaluator: "ct-scalability"
  source_artifact: "design.md"
  usefulness_score: 9
  clarity_score: 10
  useful_elements:
    - "§1.1 Before vs. After table — immediately clear what changes and what doesn't"
    - "§1.4 What Does NOT Change — explicit enumeration of preserved mechanisms eliminated false scalability concerns"
    - "§10.2 Token Cost Corrected Estimates — incorporated prior CT measurements (avg 488 tokens) directly into design for Phase 2 reference"
    - "§14 CT Findings Disposition — thorough mapping of all prior CT findings to addressed/deferred/accepted with rationale"
    - "§13.2 Lessons Learned Keyword Heuristic — Removed — acknowledged dead-on-arrival mechanism with evidence citation"
    - "§15 Phase 2 Future Work — preserves all scalability context for future design cycle"
  missing_information:
    - "No enforcement gate ensuring Phase 2 re-engages scalability review before proceeding — §15.3 lists findings to 'incorporate' but doesn't mandate CT review"
  information_not_used:
    - "§8 Security Considerations — outside scalability scope"
    - "§11 Migration & Backwards Compatibility — no scalability implications"
    - "§17 Edge Cases — all are correctness concerns, not scalability"
  inaccuracies:
    - "N/A — none identified"
  impact_on_work:
    - "N/A — none identified. The revised design's clear scope, preserved-mechanisms enumeration, and corrected token data meant minimal independent verification was needed."
```

```yaml
artifact_evaluation:
  evaluator: "ct-scalability"
  source_artifact: "feature.md"
  usefulness_score: 6
  clarity_score: 7
  useful_elements:
    - "§FR-1 Tool Restriction requirements — clear, testable, and aligned with design Phase 1 scope"
    - "§FR-6 Memory Disambiguation — relevant for confirming no new scalability-affecting mechanisms introduced"
    - "§Acceptance Criteria AC-1 through AC-3, AC-11, AC-12 — concretely verifiable Phase 1 criteria"
  missing_information:
    - "No Phase 1 / Phase 2 distinction in the spec — feature.md still describes the full Pattern B scope (FR-2 through FR-5, 23-file blast radius) without noting that design.md only covers FR-1 and FR-6"
    - "NFR-3.1 token efficiency claim ('100–250 tokens each') was corrected in design but remains inaccurate in feature.md"
  information_not_used:
    - "§FR-2 through FR-5 — all relate to memory.md elimination which is deferred to Phase 2"
    - "§Edge Cases EC-1 through EC-8 — most relate to Pattern B architecture, not Phase 1 tool restriction"
    - "§Test Scenarios TS-2 through TS-6, TS-8 through TS-10 — relate to memory.md elimination, not Phase 1"
    - "§Dependencies & Risks — most risks (20-file mass edit, missing aggregated Artifact Index) apply to deferred Phase 2"
  inaccuracies:
    - "NFR-3.1 still claims '.mem.md files (100–250 tokens each)' — prior CT review measured avg 488 tokens; corrected in design.md §10.2 but not in feature.md"
    - "Scope section (§In Scope items 2–8) does not reflect Phase 1 reduction — design only implements items 1–2 partially"
  impact_on_work:
    - "Significant mismatch between feature.md scope and design.md Phase 1 scope required cross-referencing to determine which requirements are actually in play"
```
